1-7 of 7
Jose Carlos Cruz
Close
Sort by
Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Uttam K Rao, Betsy Blunk, Carlos Bachier, Vikas Bhushan, Jose Carlos Cruz, Mohammed Elayan, Ian W. Flinn, Tara Gregory, Charles F. LeMaistre, Navneet Majhail, Shahbaz A. Malik, Casey Martin, Michael B. Maris, John Mathews, Luke Mountjoy, Jeremy M. Pantin, Aravind Ramakrishnan, Paul Shaughnessy, Michael T. Tees, Estil A. Vance, Behyar Zoghi, MD, PhD, FACP, Minoo Battiwalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 3504.
https://doi.org/10.1182/blood-2023-190388
Published: 2023
Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 651.
https://doi.org/10.1182/blood-2021-145572
Published: 2021
Journal Articles

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young
Journal: Blood
Blood (2021) 138 (Supplement 1): 2822.
https://doi.org/10.1182/blood-2021-151727
Published: 2021
Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-137685
Published: 2020
Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4780.
https://doi.org/10.1182/blood-2019-130640
Published: 2019
Journal Articles

Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 564.
https://doi.org/10.1182/blood-2018-99-110975
Published: 2018
Journal Articles

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L. Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 722.
https://doi.org/10.1182/blood.V130.Suppl_1.722.722
Published: 2017